FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569521738> ?p ?o ?g. }

• W2569521738 endingPage "4702" @default.
• W2569521738 startingPage "4702" @default.
• W2569521738 abstract "Abstract Introduction: Acquired Factor XIII deficiency due to an antibody inhibitor (AIFXIII) is a rare but life-threatening bleeding disorder. Factor XIII is a fibrin stabilizing enzyme that crosslinks fibrin monomers. Deficiency of Factor XIII results in destabilization of formed clots within 24-48 hours, resulting in delayed hemorrhage. Because the standard coagulation tests are normal, the diagnosis of this disease requires a high degree of suspicion and specialized testing. We report a case of an 88-year-old female presenting with severe hemorrhage of unknown origin. Goal: We aim to heighten the awareness amongst clinicians of the possibility of acquired FXIII deficiency when a patient presents with bleeding symptoms and normal routine coagulation tests. Case: An 88-year-old female with a recent diagnosis of autoimmune hemolytic anemia (AIHA) on oral Prednisone developed left arm swelling, pain, and ecchymosis. She denied anticoagulation and history of abnormal bleeding. CT scan of the arm showed a biceps muscle hematoma measuring 17cm in length. On day 4, she developed hematoma on the contralateral forearm, which prompted bilateral fasciotomies and evacuation. Patient continued to have bleeding from her right forearm hematoma, requiring further exploration and evacuation of multiple clots. Laboratory Tests: Her Hg dropped from 9.2 g/dl to 6.6 g/dl requiring RBC transfusions. Peripheral blood smear revealed features of chronic hemolysis. She had a normal coagulation profile including PT (11.1 sec), INR (1.05), PTT (24.4 sec), fibrinogen (295mg/dL) and normal platelet function assay. Her D-dimer was elevated at 371 ng/ml. She had a normal CRP (3.3mg/L), ANA antibody (<1:40) and ESR (23 mm/hr). SPEP showed hypoproteinemia without monoclonal bands. The patient's FVIII (307%), VWF ag (307%), VWF activity (369%), VWF collagen binding assay (412%) and alpha-2-antiplasmin (101%) were normal. Patient's Factor XIII levels were measured at 8%. We suspected this to be a case of AIFXIII. Testing for inhibitor with serial dilutions showed an antibody titer of 1:40. Results: She was started on 100 mg/d of Cyclophosphamide and continued on 20mg of Prednisone. No further hematomas developed. Patient was discharged on day 29 with a close follow up. On day 66, patient had AIHA flare (Hg: 6.6g/dL) and was treated with PRBCs, Rituximab 375mg/m^2 for 4 infusions and prednisone 40mg daily. Her Factor XIII activity on day 68 was 12% and inhibitor titer 1:10. On day 98, patient developed large ecchymoses on the right knee, thigh and buttock. Her Factor XIII activity dropped to < 10% again and inhibitor titer went up to 1:20 on serial dilution. She was transfused with PRBCs and was started on IVIG at 1000 mg/kg X 5. Cyclophosphamide was stopped and Prednisone was decreased to 10mg daily. Her Factor XIII is still <10% but inhibitor titer is down to 1:10. Patient is not actively bleeding. Discussion: There are less than 60 reported cases of AIFXIII in the literature. This is the first reported case presenting with warm antibody hemolytic anemia. Various treatments have been employed in the past for AIFXIII. It involves two strategies: hemostasis to treat acute bleeding symptoms and inhibitor eradication. Use of steroids and immunosuppressants such as Cyclophosphamide, Rituximab, and Cyclosporine has been prevalent in most of the cases to obtain inhibitor eradication. It is hard to define what combination of therapy works because most of the cases involve use of combination of these strategies and spontaneous remissions have also been seen. In this case, we suspect that patient presented with higher than expected factor XIII activity (8%) at the onset because she was already on immunosuppression for her AIHA for 2 months prior. She was refractory to first-line therapy with Rituximab and Cyclophosphamide in combination with steroids for complete inhibitor eradication. Second line therapy with IVIG was recently given and we are hopeful of a response. Conclusion: AIFXIII is a rare but life-threatening bleeding disorder that should be suspected especially when elderly patients present with hemorrhage of unknown origin and normal screening coagulation studies. Characterization of the factor XIII activity and detection of antibodies should be undertaken promptly in order to provide the best anti-hemorrhagic and inhibitor eradication treatment. Disclosures No relevant conflicts of interest to declare." @default.
• W2569521738 created "2017-01-13" @default.
• W2569521738 creator A5011348837 @default.
• W2569521738 creator A5024332142 @default.
• W2569521738 creator A5036020955 @default.
• W2569521738 date "2015-12-03" @default.
• W2569521738 modified "2023-10-01" @default.
• W2569521738 title "A Rare Case of Bleeding - Acquired Factor Inhibitors with Normal Coagulation Tests" @default.
• W2569521738 doi "https://doi.org/10.1182/blood.v126.23.4702.4702" @default.
• W2569521738 hasPublicationYear "2015" @default.
• W2569521738 type Work @default.
• W2569521738 sameAs 2569521738 @default.
• W2569521738 citedByCount "0" @default.
• W2569521738 crossrefType "journal-article" @default.
• W2569521738 hasAuthorship W2569521738A5011348837 @default.
• W2569521738 hasAuthorship W2569521738A5024332142 @default.
• W2569521738 hasAuthorship W2569521738A5036020955 @default.
• W2569521738 hasBestOaLocation W25695217381 @default.
• W2569521738 hasConcept C126322002 @default.
• W2569521738 hasConcept C141071460 @default.
• W2569521738 hasConcept C16124881 @default.
• W2569521738 hasConcept C203014093 @default.
• W2569521738 hasConcept C2776046644 @default.
• W2569521738 hasConcept C2777292125 @default.
• W2569521738 hasConcept C2778382381 @default.
• W2569521738 hasConcept C2779036427 @default.
• W2569521738 hasConcept C2779612170 @default.
• W2569521738 hasConcept C2779662492 @default.
• W2569521738 hasConcept C2779663748 @default.
• W2569521738 hasConcept C2779672106 @default.
• W2569521738 hasConcept C2780868729 @default.
• W2569521738 hasConcept C54173615 @default.
• W2569521738 hasConcept C66112548 @default.
• W2569521738 hasConcept C71924100 @default.
• W2569521738 hasConcept C89560881 @default.
• W2569521738 hasConcept C90924648 @default.
• W2569521738 hasConceptScore W2569521738C126322002 @default.
• W2569521738 hasConceptScore W2569521738C141071460 @default.
• W2569521738 hasConceptScore W2569521738C16124881 @default.
• W2569521738 hasConceptScore W2569521738C203014093 @default.
• W2569521738 hasConceptScore W2569521738C2776046644 @default.
• W2569521738 hasConceptScore W2569521738C2777292125 @default.
• W2569521738 hasConceptScore W2569521738C2778382381 @default.
• W2569521738 hasConceptScore W2569521738C2779036427 @default.
• W2569521738 hasConceptScore W2569521738C2779612170 @default.
• W2569521738 hasConceptScore W2569521738C2779662492 @default.
• W2569521738 hasConceptScore W2569521738C2779663748 @default.
• W2569521738 hasConceptScore W2569521738C2779672106 @default.
• W2569521738 hasConceptScore W2569521738C2780868729 @default.
• W2569521738 hasConceptScore W2569521738C54173615 @default.
• W2569521738 hasConceptScore W2569521738C66112548 @default.
• W2569521738 hasConceptScore W2569521738C71924100 @default.
• W2569521738 hasConceptScore W2569521738C89560881 @default.
• W2569521738 hasConceptScore W2569521738C90924648 @default.
• W2569521738 hasIssue "23" @default.
• W2569521738 hasLocation W25695217381 @default.
• W2569521738 hasOpenAccess W2569521738 @default.
• W2569521738 hasPrimaryLocation W25695217381 @default.
• W2569521738 hasRelatedWork W1608898437 @default.
• W2569521738 hasRelatedWork W1980504237 @default.
• W2569521738 hasRelatedWork W1995576073 @default.
• W2569521738 hasRelatedWork W2001836156 @default.
• W2569521738 hasRelatedWork W2150201884 @default.
• W2569521738 hasRelatedWork W2408978406 @default.
• W2569521738 hasRelatedWork W2473180043 @default.
• W2569521738 hasRelatedWork W2569521738 @default.
• W2569521738 hasRelatedWork W2676219049 @default.
• W2569521738 hasRelatedWork W4200451508 @default.
• W2569521738 hasVolume "126" @default.
• W2569521738 isParatext "false" @default.
• W2569521738 isRetracted "false" @default.
• W2569521738 magId "2569521738" @default.
• W2569521738 workType "article" @default.